Actively Recruiting

Phase 1
Phase 2
Age: 18Years - 65Years
All Genders
NCT05939167

Mesenchymal Stem Cells Treatment for AIDS Patients at Late Stage

Led by Cell Energy Life Sciences Group Co. LTD · Updated on 2025-08-12

150

Participants Needed

4

Research Sites

239 weeks

Total Duration

On this page

Sponsors

C

Cell Energy Life Sciences Group Co. LTD

Lead Sponsor

B

Beijing 302 Hospital

Collaborating Sponsor

AI-Summary

What this Trial Is About

The goal of this study is to conduct a prospective, double-blind, randomized placebo-controlled clinical trial to investigate the safety and efficacy of mesenchymal stem cells treatment for AIDS patients at late stage.

CONDITIONS

Official Title

Mesenchymal Stem Cells Treatment for AIDS Patients at Late Stage

Who Can Participate

Age: 18Years - 65Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Confirmed HIV infection
  • Age between 18 and 65 years
  • CD4+ T cell count below 500 cells/μl at baseline
  • No serious AIDS-related events
  • Able to understand and sign informed consent and comply with study requirements
  • Agree not to participate in other studies or receive other immunotherapies during the study period
Not Eligible

You will not qualify if you...

  • Positive infection with HBV, HCV, HDV, or HEV based on virological testing
  • Cytomegalovirus (CMV) or Epstein-Barr virus (EBV) viral load above 1000 copies/ml
  • Infection with HIV-2
  • Serious complications in organs such as kidney, heart, lungs, digestive system, endocrine, nervous, immune system, or tumors
  • Long-term use of hormones or other immunosuppressive drugs
  • Serious AIDS-related or unrelated events
  • Use of immunosuppressive or systemic cytotoxic drugs for more than 3 months before recruitment
  • Poor treatment compliance
  • Drug addiction within last 6 months or positive urine drug test
  • Participation in other clinical trials currently
  • Pregnancy, breastfeeding, or fertility requirements
  • Unable or unwilling to provide informed consent or comply with study requirements
  • Other serious conditions that may interfere with the trial

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 4 locations

1

Beijing 302 Hospital

Beijing, China

Actively Recruiting

2

Beijing YouAn Hospital

Beijing, China

Actively Recruiting

3

Shenzhen Third People's Hospital

Shenzhen, China

Actively Recruiting

4

The Fifth Hospital of Shijiazhuang

Shijiazhuang, China

Actively Recruiting

Loading map...

Research Team

F

Fu-Sheng Wang, Doctor

CONTACT

R

Robert Chunhua Zhao, Doctor

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here